Evidence map›Paper›PMID 42434285›Full record

ArticleJournal of gastrointestinal oncology2026

Histopathologic, molecular, and clinical associations of fusion-positive gastrointestinal carcinomas.

Bennett A Caughey, Sean T Bannon, Chloe Simms, Haley Barnes, Leontios Pappas, Valentina Nardi, Dora Dias-Santagata, A John Iafrate, Ryan B Corcoran, Charlotte I Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bennett A CaugheyDivision of Hematology-Oncology, Massachusetts General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-3970-1651
Sean T BannonDivision of Hematology-Oncology, Massachusetts General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Chloe SimmsDivision of Hematology-Oncology, Massachusetts General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Haley BarnesDivision of Hematology-Oncology, Massachusetts General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0003-2190-8969
Leontios PappasDivision of Hematology-Oncology, Massachusetts General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-0589-8265
Valentina NardiDepartment of Pathology, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-0486-416X
Dora Dias-SantagataDepartment of Pathology, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-1174-3972
A John IafrateDepartment of Pathology, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-7888-4067
Ryan B Corcoran *Division of Hematology-Oncology, Massachusetts General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0001-8173-5778
Charlotte I Wang *Department of Pathology, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0009-0000-3512-8635

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Comprehensive genomic profiling (CGP) is critical for optimal clinical care for gastrointestinal (GI) carcinomas. Outside of biliary tract cancers (BTCs), actionable fusions are uncommon and the utility of routine RNA-based fusion testing in GI cancers is not well established. We therefore evaluated routinely conducted RNA-based fusion testing in GI cancers at a single center. Methods: Patients with GI carcinomas who underwent RNA-based tissue fusion testing at Massachusetts General Brigham Cancer Institute were included. Tumors with fusions were characterized for molecular and histopathologic associations. Results: A total of 2,300 patients with GI carcinomas were included; 139 (6.0%) had a detected fusion. BTCs had the highest fusion incidence (13.7%), mostly Conclusions: RNA-based testing identifies potentially actionable fusions in a clinically significant fraction of GI carcinomas. Patients who receive fusion targeted therapy during their clinical course demonstrate longer survival, supporting CGP including fusion testing for all patients. Lower GI cancers harboring

Indexed as

Gastrointestinal malignancies (GI malignancies)gene fusionsprecision oncology

Identifiers

PMID42434285
PMCPMC13350599

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.